I compiled a summary of US sales for DAYBUE and SKYCLARYS, same launch time, DAYBUE has been performing better than SKYCLARYS in sales in US.
Given SKYCLARYS/Reata was acquired in 2023 for US$7.3B, NEU is still valued at US$1.05B with net cash around $320m including US$50m milestone payment to receive this quarter less accrued income tax.
According to Acadia sale guidance, NEU will receive royalties for 2025 DAYBUE sales, royalties will be around $64m to $69m, then likely another milestone payment for first Europe sale of US$35m/$55m, and bank interest income around $16m, NEU 2025 income are likely to be around $135m to $140m, on top of existing net cash position of around $320m, based on my estimates.
DYOR & ALL IMO.
![]()
- Forums
- ASX - By Stock
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.69%
!
$14.20

I compiled a summary of US sales for DAYBUE and SKYCLARYS, same...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B |
Open | High | Low | Value | Volume |
$13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $14.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.23 | 3278 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1300 | 14.030 |
1 | 500 | 14.000 |
1 | 357 | 13.970 |
1 | 30 | 13.900 |
1 | 700 | 13.700 |
Price($) | Vol. | No. |
---|---|---|
14.260 | 2920 | 1 |
14.300 | 1000 | 1 |
14.380 | 72 | 1 |
14.400 | 1000 | 1 |
14.460 | 434 | 1 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online